Description
The lungs are considered by many to be the best alternative for drugs needing to bypass the gastrointestinal tract. With advancing technology, the practice of utilizing the huge surface area of the lungs to delivery drugs into the blood circulation has been slowly transforming into reality.
The pulmonary drug delivery market reached $25.5 billion in 2006 and is expected to experience high steady growth in the next five years. Contributing to growth are new technologies such as dry powder inhalers and new product offerings that require advanced drug delivery. Pulmonary drug delivery offers the potential for non-invasive administration of a wide variety of macromolecules. Nearly every biotherapeutic product that treats chronic or long-term illness would benefit from noninvasive delivery by providing a competitive advantage with current therapeutics. This advantage could expand the market for each product or enable new indications to be considered.
Kalorama’s Drug Delivery Markets. Edition 2 Volume III: Pulmonary Delivery Systems, the third volume of Kalorama’s popular series focusing on global drug delivery systems markets, provides the definitive break down of the market for pulmonary delivery system markets. The report covers both pharmaceuticals sold through pulmonary delivery systems and the technologies themselves
The report provides current market size and revenue for the following main categories:
- Inhalation drug delivery
- Intranasal drug delivery
Kalorama believes the future of drug administration by inhalation will expand vastly and be a significant driver in this market. Serious market-watchers who are looking at new products or ways to expand existing products will find this information essential.
As part of its comprehensive cooverage, Kalorama’s report includes:
- A Breakdown of Demographics and Trends that will drive pulmonary delivery.
- New Developments including Prodrug Technology, Electrohydrodynamic
Aerosol Delivery, Oxygen Delivery and Crystallization Technology
- Detailed Discussion of Current Products in pulmonary drug delivery.
- Current Market Size and Forecasts to 2010.
- Review of Pipleline products
- Profiles of Key Companies in the Pulmonary Delivery markets.
As part of Kalorama’s trusted information-gathering process, industry executives are interviewed. While government and company data is culled, it is interviews with executives that provide the foundation for market sizes and forecasts.
Kalorama’s coverage of the pulmonary drug delivery market includes coverage of the following companies in this field:
- 3M
- Alkermes
- Aradigm
- Elan
- Nastech
- Nektar
- SkyePharma
Table of Contents
Chapter one: Executive Summary
- Market Drivers
- Market Size and Growth
- The Total Pulmonary Drug Delivery Market
- The Total Pulmonary Drug Delivery Only Market
- Competitor and Market Analysis
Chapter two: Introduction and Overview
- Scope and Methodology
- Reasons for pulmonary Drug Delivery Systems
- History and Mechanics of Pulmonary Drug Delivery
- Phases of Drug Action
- Pharmacokinetics of Inhalation
- Inhalation Delivery Technologies
- Metered Dose Inhalers
- Dry Powder Formulations
- Nebulizer Delivery Formulations
- Liquid Formulations
- Nanospheres
- Intranasal Delivery Technologies
Chapter three: Trends and Demographics
- Asthma
- Opportunities for Drug Delivery System Success
- Exubera Breakthrough
- Nano and Microparticulate Systems
- Trends in Liquid Aerosols
- CFC Phase Out
- Expansion of Biotechnology
- Macromolecule Delivery
Chapter four: New Developments
- Prodrug Drug Delivery
- Electrohydrodynamic Aerosol Delivery
- Oxygen Delivery
- Crystallization Technology
Chapter five: Market Size and Growth
- The Total Pulmonary Drug Delivery Market
- Pulmonary Delivery Technology Only Market
Chapter six: Competitive and Market Analysis
- Competitor Analysis
- Market Analysis
Chapter seven: Company Profiles
- 3M Pharmaceuticals
- Alkermes, Inc.
- Aradigm Corporation
- Elan Corporation, Plc
- Innovata BioMed Plc
- MicroDose Technology, Inc
- Nastech Pharmaceutical Company Inc.
- Nektar Therapeutics
- Oriel Therapeutics
- Pipex Pharmaceuticals
- Resiprics, Inc.
- SkyePharma Plc
- Vectura Ltd.
- Ventaira Pharmaceuticals, Inc.
Chapter eight: Companies in Brief
- Bespak
- Direct Haler A/S
- IntraNasal Therapeutics
Appendix: Company Directory
TAble of exhibits
Chapter one: Executive Summary
- Table 1-1: The Worldwide Market for Pulmonary Drug Delivery Technology and Pharmaceuticals 2002-2010
- Figure 1-1: The Worldwide Market for Pulmonary Drug Delivery Technology and Pharmaceuticals 2002-2010
- Table 1-2: The Worldwide Market for Pulmonary Drug Delivery Systems by Pharmaceutical and Drug Delivery Component 2002-2010
- Figure 1-2: The Worldwide Market for Pulmonary Drug Delivery Systems Distribution of Revenue by Pharmaceutical and Drug Delivery Component 2002-2010
Chapter two: Introduction and Overview
- Table 2-1: Sequence of Drug Action
Chapter three: Trends and Demographics
- Table 3-1: Worldwide Prevalence of Asthma 2006
- Figure 3-1: Worldwide Prevalence of Asthma 2006
- Table 3-2: World Population by Age Group 2002-2010
- Figure 3-2: World Population by Age Group 2002-2010
Chapter fivE: Market Size and Growth
- Table 5-1: The Worldwide Market for Pulmonary Drug Delivery Technology and Pharmaceuticals 2002-2010
- Figure 5-1: The Worldwide Market for Pulmonary Drug Delivery Technology and Pharmaceuticals 2002-2010
- Table 5-2: The Worldwide Market for Pharmaceuticals Utilizing Pulmonary Drug Delivery Systems by Type 2002-2010
- Figure 5-2: The Worldwide Market for Pharmaceuticals Utilizing Pulmonary Drug Delivery Systems Revenues by Type 2002-2010
- Table 5-3: The Worldwide Market for Pharmaceuticals Utilizing Pulmonary Drug Delivery Technologies Market Share by Type 2002-2010
- Figure 5-3: The Worldwide Market for Pharmaceuticals Utilizing Pulmonary Drug Delivery Technologies by Type 2006
- Figure 5-4: The Worldwide Market for Pharmaceuticals Utilizing Pulmonary Drug Delivery Technologies by Type 2010
- Table 5-4: The Worldwide Market for Pulmonary Drug Delivery Systems by Pharmaceutical and Drug Delivery Component 2002-2010
- Table 5-5 of Revenue by Pharmaceutical and Drug Delivery Component 2002-2010
- Figure 5-5 of Revenue by Pharmaceutical and Drug Delivery Component 2002-2010
- Figure 5-6: The Worldwide Market for Pulmonary Drug Delivery Systems Distribution of Revenue by Pharmaceutical and Drug Delivery Component 2006
- Figure 5-7: The Worldwide Market for Pulmonary Drug Delivery Systems Distribution of Revenue by Pharmaceutical and Drug Delivery Component 2010
Chapter six: Competitive and Market Analysis
- Table 6-1: Selected Leading and Emerging Suppliers of Pulmonary Drug
- Delivery Technology
